Cowen Starts Loxo Oncology (LOXO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil slips but stays near six-month highs on Saudi attacks
- BofA flags further downside risk for stocks, yields and dollar
Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy
September 2, 2014 6:54 AM EDTStifel Nicolaus initiated coverage on Loxo Oncology (NASDAQ: LOXO) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.
Shares of Loxo Oncology closed at $13.01 yesterday.
... MoreOppenheimer Starts Loxo Oncology (LOXO) at Outperform
September 2, 2014 6:28 AM EDTOppenheimer initiates coverage on Loxo Oncology (NASDAQ: LOXO) with a Outperform rating and a price target of $20.00.
Analyst Yigal Nochomovitz, Ph.D. commented, "Loxo is an early-stage biotechnology company executing a business plan for targeted cancer drugs that benefits from 1) clear precedent for... More



